Omicron And Acquisitions Push Up Galenica's Swiss OTC Sales By A Third
Galenica's Verfora substantially outpaced the 6.4% growth rate of the Swiss consumer health market in the first half, posting sales up by a third thanks to a combination of acquisitions and increased demand for cold & flu products due to the spread of the COVID-19 Omicron variant.
You may also be interested in...
Boiron Partners With Galenica's Verfora In Switzerland
France's Boiron has granted Galenica's Verfora the rights to distribute in Switzerland its portfolio of over 800 products as it looks to turnaround its business and make cost savings following the collapse of homeopathy sales in its home market.
EU Business Round-Up: Galenica Acquires Spagyros, Karo Offloads OTCs, And Ceres Gets New Owners
The latest European business news: Galenica strengthens its porfolio in Switzerland with Spagyros; Sweden's Karo offloads OTCs to Evolan; and Ceres Pharma sold to French private-equity firm.
Galenica Grows In Switzerland With Dr. Wild OTC Portfolio
Galenica has acquired an OTC portfolio from Switzerland's Dr. Wild, led by the market leading vitamin D supplements Vitamin D3 Wild Oil and VI-DE 3, which generated sales of CHF19m in 2020.